To further investigate the potential therapeutic effect of rSema3A on TGF-β–induced AF, we intravenously injected TGF-β–transgenic mice with rSema3A (1 mg/kg; refs. 41, 42) or PBS twice weekly for 4 weeks (Supplemental Figure 10A). Here, TGFB1 is linked to atrial fibrillation.